Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma

Arnoldo Piccardo, Matteo Puntoni, Egesta Lopci, Massimo Conte, Luca Foppiani, Stefania Sorrentino, Giovanni Morana, Mehrdad Naseri, Angelina Cistaro, Giampiero Villavecchia, Stefano Fanti, Alberto Garaventa

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: The aim of this study was to investigate the relationship between 123I-metaiodobenzylguanidine (MIBG) scan semi-quantification and a new 18F-DOPA positron emission tomography (PET)/CT score in patients with suspected or documented neuroblastoma (NB) relapse and to assess the association between these two parameters and progression-free survival (PFS)/overall survival (OS). Methods: We analysed 24 NB patients who had undergone 123I-MIBG and 18F-DOPA PET/CT scans at the time of suspected relapse, after applying a proper scoring system for each scan. In time-to-event analyses, the score distributions were regarded as continuous and were categorized in tertiles and medians. We used Kaplan-Meier curves and Cox proportional hazard models for PFS and OS in order to estimate the independent prognostic impact of 123I-MIBG and 18F-DOPA PET/CT scans. Results: The 123I-MIBG and 18F-DOPA scores were highly and positively correlated (Spearman's rho=0.8, p123I-MIBG score>3 (3rd tertile) and an even higher risk (HR:37.2, 95 % CI 2.4-574) in those with 18F-DOPA whole-body metabolic burden (WBMB) >7.5 (median), after adjustment for all main clinical/pathological factors considered. Kaplan-Meier analyses showed a significant association with OS (log-rank p=0.01 and p=0.03 for 123I-MIBG and 18F-DOPA WBMB, respectively). Conclusion: Our results confirm the good agreement between 18F-DOPA PET/CT and 123I-MIBG scan in patients affected by NB relapse. In time-to-event analyses, 123I-MIBG scan and 18F-DOPA PET/CT scores were independently and significantly associated with disease progression.

Original languageEnglish
Pages (from-to)1046-1056
Number of pages11
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume41
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Neuroblastoma
Positron-Emission Tomography
Recurrence
Body Burden
Disease-Free Survival
Survival
Kaplan-Meier Estimate
Proportional Hazards Models
Disease Progression

Keywords

  • Neuroblastoma
  • Prognostic value

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. / Piccardo, Arnoldo; Puntoni, Matteo; Lopci, Egesta; Conte, Massimo; Foppiani, Luca; Sorrentino, Stefania; Morana, Giovanni; Naseri, Mehrdad; Cistaro, Angelina; Villavecchia, Giampiero; Fanti, Stefano; Garaventa, Alberto.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, No. 6, 2014, p. 1046-1056.

Research output: Contribution to journalArticle

Piccardo, Arnoldo ; Puntoni, Matteo ; Lopci, Egesta ; Conte, Massimo ; Foppiani, Luca ; Sorrentino, Stefania ; Morana, Giovanni ; Naseri, Mehrdad ; Cistaro, Angelina ; Villavecchia, Giampiero ; Fanti, Stefano ; Garaventa, Alberto. / Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. In: European Journal of Nuclear Medicine and Molecular Imaging. 2014 ; Vol. 41, No. 6. pp. 1046-1056.
@article{f41c3fd257a94fe38a556a4ac3b92b7e,
title = "Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma",
abstract = "Purpose: The aim of this study was to investigate the relationship between 123I-metaiodobenzylguanidine (MIBG) scan semi-quantification and a new 18F-DOPA positron emission tomography (PET)/CT score in patients with suspected or documented neuroblastoma (NB) relapse and to assess the association between these two parameters and progression-free survival (PFS)/overall survival (OS). Methods: We analysed 24 NB patients who had undergone 123I-MIBG and 18F-DOPA PET/CT scans at the time of suspected relapse, after applying a proper scoring system for each scan. In time-to-event analyses, the score distributions were regarded as continuous and were categorized in tertiles and medians. We used Kaplan-Meier curves and Cox proportional hazard models for PFS and OS in order to estimate the independent prognostic impact of 123I-MIBG and 18F-DOPA PET/CT scans. Results: The 123I-MIBG and 18F-DOPA scores were highly and positively correlated (Spearman's rho=0.8, p123I-MIBG score>3 (3rd tertile) and an even higher risk (HR:37.2, 95 {\%} CI 2.4-574) in those with 18F-DOPA whole-body metabolic burden (WBMB) >7.5 (median), after adjustment for all main clinical/pathological factors considered. Kaplan-Meier analyses showed a significant association with OS (log-rank p=0.01 and p=0.03 for 123I-MIBG and 18F-DOPA WBMB, respectively). Conclusion: Our results confirm the good agreement between 18F-DOPA PET/CT and 123I-MIBG scan in patients affected by NB relapse. In time-to-event analyses, 123I-MIBG scan and 18F-DOPA PET/CT scores were independently and significantly associated with disease progression.",
keywords = "Neuroblastoma, Prognostic value",
author = "Arnoldo Piccardo and Matteo Puntoni and Egesta Lopci and Massimo Conte and Luca Foppiani and Stefania Sorrentino and Giovanni Morana and Mehrdad Naseri and Angelina Cistaro and Giampiero Villavecchia and Stefano Fanti and Alberto Garaventa",
year = "2014",
doi = "10.1007/s00259-014-2691-0",
language = "English",
volume = "41",
pages = "1046--1056",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "6",

}

TY - JOUR

T1 - Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma

AU - Piccardo, Arnoldo

AU - Puntoni, Matteo

AU - Lopci, Egesta

AU - Conte, Massimo

AU - Foppiani, Luca

AU - Sorrentino, Stefania

AU - Morana, Giovanni

AU - Naseri, Mehrdad

AU - Cistaro, Angelina

AU - Villavecchia, Giampiero

AU - Fanti, Stefano

AU - Garaventa, Alberto

PY - 2014

Y1 - 2014

N2 - Purpose: The aim of this study was to investigate the relationship between 123I-metaiodobenzylguanidine (MIBG) scan semi-quantification and a new 18F-DOPA positron emission tomography (PET)/CT score in patients with suspected or documented neuroblastoma (NB) relapse and to assess the association between these two parameters and progression-free survival (PFS)/overall survival (OS). Methods: We analysed 24 NB patients who had undergone 123I-MIBG and 18F-DOPA PET/CT scans at the time of suspected relapse, after applying a proper scoring system for each scan. In time-to-event analyses, the score distributions were regarded as continuous and were categorized in tertiles and medians. We used Kaplan-Meier curves and Cox proportional hazard models for PFS and OS in order to estimate the independent prognostic impact of 123I-MIBG and 18F-DOPA PET/CT scans. Results: The 123I-MIBG and 18F-DOPA scores were highly and positively correlated (Spearman's rho=0.8, p123I-MIBG score>3 (3rd tertile) and an even higher risk (HR:37.2, 95 % CI 2.4-574) in those with 18F-DOPA whole-body metabolic burden (WBMB) >7.5 (median), after adjustment for all main clinical/pathological factors considered. Kaplan-Meier analyses showed a significant association with OS (log-rank p=0.01 and p=0.03 for 123I-MIBG and 18F-DOPA WBMB, respectively). Conclusion: Our results confirm the good agreement between 18F-DOPA PET/CT and 123I-MIBG scan in patients affected by NB relapse. In time-to-event analyses, 123I-MIBG scan and 18F-DOPA PET/CT scores were independently and significantly associated with disease progression.

AB - Purpose: The aim of this study was to investigate the relationship between 123I-metaiodobenzylguanidine (MIBG) scan semi-quantification and a new 18F-DOPA positron emission tomography (PET)/CT score in patients with suspected or documented neuroblastoma (NB) relapse and to assess the association between these two parameters and progression-free survival (PFS)/overall survival (OS). Methods: We analysed 24 NB patients who had undergone 123I-MIBG and 18F-DOPA PET/CT scans at the time of suspected relapse, after applying a proper scoring system for each scan. In time-to-event analyses, the score distributions were regarded as continuous and were categorized in tertiles and medians. We used Kaplan-Meier curves and Cox proportional hazard models for PFS and OS in order to estimate the independent prognostic impact of 123I-MIBG and 18F-DOPA PET/CT scans. Results: The 123I-MIBG and 18F-DOPA scores were highly and positively correlated (Spearman's rho=0.8, p123I-MIBG score>3 (3rd tertile) and an even higher risk (HR:37.2, 95 % CI 2.4-574) in those with 18F-DOPA whole-body metabolic burden (WBMB) >7.5 (median), after adjustment for all main clinical/pathological factors considered. Kaplan-Meier analyses showed a significant association with OS (log-rank p=0.01 and p=0.03 for 123I-MIBG and 18F-DOPA WBMB, respectively). Conclusion: Our results confirm the good agreement between 18F-DOPA PET/CT and 123I-MIBG scan in patients affected by NB relapse. In time-to-event analyses, 123I-MIBG scan and 18F-DOPA PET/CT scores were independently and significantly associated with disease progression.

KW - Neuroblastoma

KW - Prognostic value

UR - http://www.scopus.com/inward/record.url?scp=84900789874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900789874&partnerID=8YFLogxK

U2 - 10.1007/s00259-014-2691-0

DO - 10.1007/s00259-014-2691-0

M3 - Article

C2 - 24562643

AN - SCOPUS:84900789874

VL - 41

SP - 1046

EP - 1056

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 6

ER -